Comparative bioinformatics analysis of the Wnt pathway in breast cancer: Selection of novel biomarker panels associated with ER status. (PubMed, Open Life Sci)
Thus, this study revealed potential diagnostic and prognostic signatures based on comprehensive analyses of BC patient data sourced from The Cancer Genome Atlas database. Consequently, four gene signatures were constructed: two differentiate ER+ from ER-BC: TTC8, SLC5A7, and PLCH1 for overall survival (OS); ZNF695, SLC7A5, and PLCH1 for disease free survival (DFS), while the other two effectively distinguish tumor from normal samples: SPC25, ANLN, KPNA2, SLC7A5 for OS; SPC25, KIF20A, SKA3, DTL, CDCA3, ANLN, TTK, RAD54L, MYBL2, ZNF695, and SLC7A5 for DFS.